Correlation Between Intersport Polska and Medicofarma Biotech

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Intersport Polska and Medicofarma Biotech at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Intersport Polska and Medicofarma Biotech into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Intersport Polska SA and Medicofarma Biotech SA, you can compare the effects of market volatilities on Intersport Polska and Medicofarma Biotech and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Intersport Polska with a short position of Medicofarma Biotech. Check out your portfolio center. Please also check ongoing floating volatility patterns of Intersport Polska and Medicofarma Biotech.

Diversification Opportunities for Intersport Polska and Medicofarma Biotech

0.72
  Correlation Coefficient

Poor diversification

The 3 months correlation between Intersport and Medicofarma is 0.72. Overlapping area represents the amount of risk that can be diversified away by holding Intersport Polska SA and Medicofarma Biotech SA in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Medicofarma Biotech and Intersport Polska is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Intersport Polska SA are associated (or correlated) with Medicofarma Biotech. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Medicofarma Biotech has no effect on the direction of Intersport Polska i.e., Intersport Polska and Medicofarma Biotech go up and down completely randomly.

Pair Corralation between Intersport Polska and Medicofarma Biotech

Assuming the 90 days trading horizon Intersport Polska SA is expected to under-perform the Medicofarma Biotech. In addition to that, Intersport Polska is 1.19 times more volatile than Medicofarma Biotech SA. It trades about -0.12 of its total potential returns per unit of risk. Medicofarma Biotech SA is currently generating about -0.09 per unit of volatility. If you would invest  40.00  in Medicofarma Biotech SA on December 2, 2024 and sell it today you would lose (12.00) from holding Medicofarma Biotech SA or give up 30.0% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy98.33%
ValuesDaily Returns

Intersport Polska SA  vs.  Medicofarma Biotech SA

 Performance 
       Timeline  
Intersport Polska 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Intersport Polska SA has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.
Medicofarma Biotech 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Medicofarma Biotech SA has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Intersport Polska and Medicofarma Biotech Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Intersport Polska and Medicofarma Biotech

The main advantage of trading using opposite Intersport Polska and Medicofarma Biotech positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Intersport Polska position performs unexpectedly, Medicofarma Biotech can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medicofarma Biotech will offset losses from the drop in Medicofarma Biotech's long position.
The idea behind Intersport Polska SA and Medicofarma Biotech SA pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.

Other Complementary Tools

Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk